Literature DB >> 18383261

Evaluating local hepatocellular carcinoma recurrence post-transcatheter arterial chemoembolization: is diffusion-weighted MRI reliable as an indicator?

Satoshi Goshima1, Masayuki Kanematsu, Hiroshi Kondo, Ryujiro Yokoyama, Yusuke Tsuge, Yoshimune Shiratori, Minoru Onozuka, Noriyuki Moriyama.   

Abstract

PURPOSE: To evaluate the detectability of local hepatocellular carcinoma (HCC) recurrence after transcatheter arterial chemoembolization (TACE) by diffusion-weighted MR imaging in correlation with those of gadolinium-enhanced MR imaging.
MATERIALS AND METHODS: Respiratory-triggered diffusion-weighted MR images (b factor, 500 s/mm(2); number of averaging, six were obtained in 25 patients with 39 HCCs. Two independent radiologists evaluated diffusion-weighted MR images, gadolinium-enhanced MR images after TACE, and assigned confidence levels for postoperative HCC recurrence. Apparent diffusion coefficients (ADCs) in HCCs were also measured. Sensitivities and specificities were compared using an extension of the McNemar test. Observer performance was also determined by ROC curve analysis.
RESULTS: Local recurrences in 14 HCCs and complete tumor necrosis in 25 HCCs after TACE were determined. Sensitivity for the detection of local HCC recurrence was higher on gadolinium-enhanced MR imaging (82%) than on diffusion-weighted MR imaging (60.7%) for the two readers in combination and separately (P < 0.05). Specificities were comparably high for both sequences. Az values were higher for gadolinium-enhanced MR images (0.92) than for diffusion-weighted MR images (0.74) for readers in combination and separately (P < 0.05). Mean ADC values showed an increase after TACE (P < 0.001).
CONCLUSION: Diffusion-weighted MR imaging was not found to be a reliable predictor of local HCC recurrence after TACE as compared with gadolinium-enhanced MR imaging. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18383261     DOI: 10.1002/jmri.21316

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  23 in total

1.  Novel imaging biomarkers of response to transcatheter arterial chemoembolization in hepatocellular carcinoma patients.

Authors:  Sylvain Favelier; Louis Estivalet; Pierre Pottecher; Romaric Loffroy
Journal:  Chin J Cancer Res       Date:  2015-12       Impact factor: 5.087

Review 2.  Novel functional magnetic resonance imaging biomarkers for assessing response to therapy in hepatocellular carcinoma.

Authors:  Z Yuan; W-T Li; X-D Ye; H-Y Zhu; W-J Peng
Journal:  Clin Transl Oncol       Date:  2013-12-20       Impact factor: 3.405

Review 3.  Diffusion weighted imaging in the liver.

Authors:  Petra G Kele; Eric J van der Jagt
Journal:  World J Gastroenterol       Date:  2010-04-07       Impact factor: 5.742

4.  Abdominal applications of diffusion-weighted magnetic resonance imaging: Where do we stand.

Authors:  Ajaykumar C Morani; Khaled M Elsayes; Peter S Liu; William J Weadock; Janio Szklaruk; Jonathan Russell Dillman; Asra Khan; Thomas L Chenevert; Hero K Hussain
Journal:  World J Radiol       Date:  2013-03-28

5.  Diffusion-weighted imaging of the liver: usefulness of ADC values in the differential diagnosis of focal lesions and effect of ROI methods on ADC measurements.

Authors:  João Pedro Filipe; Luís Curvo-Semedo; João Casalta-Lopes; Maria Cristina Marques; Filipe Caseiro-Alves
Journal:  MAGMA       Date:  2012-10-06       Impact factor: 2.310

6.  Hepatocellular carcinoma after locoregional therapy: Magnetic resonance imaging findings in falsely negative exams.

Authors:  David Becker-Weidman; Jesse M Civan; Sandeep P Deshmukh; Christopher G Roth; Steven K Herrine; Laurence Parker; Donald G Mitchell
Journal:  World J Hepatol       Date:  2016-06-08

Review 7.  Imaging Modalities for Assessment of Treatment Response to Nonsurgical Hepatocellular Carcinoma Therapy: Contrast-Enhanced US, CT, and MRI.

Authors:  Yasunori Minami; Masatoshi Kudo
Journal:  Liver Cancer       Date:  2015-04-08       Impact factor: 11.740

Review 8.  New paradigm for management of hepatocellular carcinoma by imaging.

Authors:  Ijin Joo; Byung Ihn Choi
Journal:  Liver Cancer       Date:  2012-09       Impact factor: 11.740

Review 9.  New approaches for precise response evaluation in hepatocellular carcinoma.

Authors:  Koichi Hayano; Jorge M Fuentes-Orrego; Dushyant V Sahani
Journal:  World J Gastroenterol       Date:  2014-03-28       Impact factor: 5.742

Review 10.  Therapy response with diffusion MRI: an update.

Authors:  Lauren J Bains; Martin Zweifel; Harriet C Thoeny
Journal:  Cancer Imaging       Date:  2012-09-28       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.